Steven L. Hoerter
Net Worth
Last updated:
What is Steven L. Hoerter net worth?
The estimated net worth of Mr. Steven L. Hoerter is at least $7,327,981 as of 13 Dec 2023. He has earned $1,327,981 from insider trading and has received compensation worth at least $6,000,000 in Deciphera Pharmaceuticals, Inc..
What is the salary of Steven L. Hoerter?
Mr. Steven L. Hoerter salary is $1,200,000 per year as Pres, Chief Executive Officer & Director in Deciphera Pharmaceuticals, Inc..
How old is Steven L. Hoerter?
Mr. Steven L. Hoerter is 54 years old, born in 1971.
What stocks does Steven L. Hoerter currently own?
As insider, Mr. Steven L. Hoerter owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Deciphera Pharmaceuticals, Inc. (DCPH) | Pres, Chief Executive Officer & Director | 72,763 | $0 | $0 |
What does Deciphera Pharmaceuticals, Inc. do?
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Steven L. Hoerter insider trading
Deciphera Pharmaceuticals, Inc.
Mr. Steven L. Hoerter has made 4 insider trades between 2020-2023, according to the Form 4 filled with the SEC. Most recently he sold 30,664 units of DCPH stock worth $471,214 on 13 Dec 2023.
The largest trade he's ever made was exercising 30,664 units of DCPH stock on 13 Dec 2023. As of 13 Dec 2023 he still owns at least 72,763 units of DCPH stock.
Deciphera Pharmaceuticals key executives
Deciphera Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Daniel L. Flynn Ph.D. (70) Executive Vice President, Chief Scientific Officer & Founder
- Dr. Matthew L. Sherman (69) Executive Vice President & Chief Medical Officer
- Dr. Stephen B. Ruddy Ph.D. (61) Senior Vice President & Chief Technical Officer
- Mr. Daniel C. Martin (50) Senior Vice President & Chief Commercial Officer
- Mr. Steven L. Hoerter (54) Pres, Chief Executive Officer & Director
- Mr. Thomas Patrick Kelly J.D. (54) Executive Vice President, Chief Financial Officer & Treasurer